Important options available — from start to finish — for translating proteomics results to clinical chemistry. Issue 1 (22nd January 2015)

• Record Type: Journal Article
• Authors: Heegaard, Niels H. H.; Østergaard, Ole; Bahl, Justyna M. C.; Overgaard, Martin; Beck, Hans C.; Rasmussen, Lars Melholt; Larsen, Martin R.; Dunn, Michael J.
• Is Part Of: Proteomics. Volume 9:Issue 1/2(2015)
• Page Start: 235
• Page End: 252
• Publication Date: 2015-01-22
• Subjects: Proteomics -- Periodicals; 572.605
• DOI: 10.1002/prca.201400137
• Languages: English
• ISSNs: 1862-8346

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <p>In the realm of clinical chemistry, the field of clinical proteomics, that is, the application of proteomic methods for understanding mechanisms and enabling diagnosis, prediction, measurement of activity, and treatment response in disease, is first and foremost a discovery and research tool that feeds assay development downstream. Putative new assay candidates generated by proteomics discovery projects compete with well‐established assays with known indications, well‐described performance, and of known value in specific clinical settings. Careful attention to the many options available in the design, execution, and interpretation of clinical proteomics studies is thus necessary for translation into clinical practice. We here review and discuss important options associated with clinical proteomics endeavors stretching from the planning phases to the final use in clinical chemistry.</p> </abstract>